Peptide Half-Life Chart: The Complete Reference Guide for Researchers

Why Peptide Half-Life Matters in Research

If you are serious about peptide research, understanding half-life is non-negotiable. Half-life determines how long a peptide remains biologically active in a system, directly influencing dosing frequency, stability protocols, and experimental design. Without this knowledge, research outcomes become inconsistent and difficult to replicate.

This complete reference guide breaks down the half-lives of the most studied research peptides available today, from short-acting secretagogues to long-acting structural repair peptides. Bookmark this page — you will come back to it often.

What Is Peptide Half-Life?

Half-life (t½) refers to the time it takes for the concentration of a peptide in a biological system to reduce by 50%. This is governed by enzymatic degradation, renal clearance, and receptor binding kinetics. Peptides are inherently fragile molecules, and most are broken down rapidly by proteases present in blood and tissue.

Two primary half-life types are relevant to peptide researchers: plasma half-life, which measures degradation in circulating blood, and biological half-life, which reflects how long a peptide exerts its downstream effects. These values are not always identical.

Complete Peptide Half-Life Reference Chart

The following data is drawn from published preclinical studies, pharmacokinetic analyses, and peer-reviewed literature. All values represent approximate ranges and may vary based on administration route, formulation, and biological context.

Healing and Recovery Peptides

• BPC-157 — Plasma half-life: approximately 4 hours (subcutaneous); research suggests stable activity for up to 24 hours at tissue level. A 2018 study in the Journal of Physiology-Paris noted its remarkable stability relative to other gut-derived peptides. [INTERNAL LINK: /products/bpc-157]
• TB-500 (Thymosin Beta-4) — Half-life: estimated 4 to 6 days due to its 43-amino-acid sequence and resistance to rapid proteolysis. Studies indicate it distributes broadly into tissue compartments, extending its functional window significantly.
• GHK-Cu (Copper Peptide) — Plasma half-life: approximately 30 to 60 minutes; however, tissue-bound copper complexes may remain active considerably longer. Research suggests strong affinity for extracellular matrix proteins.

Growth Hormone Secretagogues

• CJC-1295 (without DAC) — Half-life: approximately 30 minutes. This modified GHRH analog is designed for pulsatile GH release and requires frequent administration intervals in research protocols. [INTERNAL LINK: /products/cjc-1295]
• CJC-1295 with DAC (Drug Affinity Complex) — Half-life: 6 to 8 days. The DAC modification allows albumin binding, dramatically extending circulation time. A 2006 study published in the Journal of Clinical Endocrinology and Metabolism documented sustained GH elevation over multiple days.
• Ipamorelin — Half-life: approximately 2 hours. Studies indicate a selective GH pulse with minimal cortisol or prolactin influence, making it a widely used secretagogue in combination research protocols.
• GHRP-6 — Half-life: 15 to 60 minutes. Rapid degradation necessitates frequent dosing windows in active research models. Research suggests strong ghrelin receptor affinity despite short activity duration.
• GHRP-2 — Half-life: approximately 30 minutes. Similar to GHRP-6 in kinetics but with noted differences in downstream signaling profiles per preclinical literature.
• Sermorelin — Half-life: 10 to 20 minutes. One of the shortest-acting GHRH analogs; studies indicate rapid enzymatic clearance requiring precise timing in research applications.
• Hexarelin — Half-life: approximately 70 minutes, slightly longer than other GHRPs due to structural modifications that confer mild protease resistance.

Cognitive and Neuropeptides

• Semax — Half-life: approximately 20 minutes in plasma; however, research suggests its cognitive effects may persist for several hours due to receptor-mediated downstream cascades in neurological tissue.
• Selank — Half-life: approximately 1 to 2 minutes in plasma. Despite ultra-rapid degradation, studies indicate prolonged anxiolytic-like effects lasting up to 24 hours, suggesting metabolite activity.
• DSIP (Delta Sleep-Inducing Peptide) — Half-life: approximately 30 minutes. Research suggests its effects on sleep architecture may outlast its plasma presence significantly.
• Dihexa — Half-life: estimated several hours to days due to high lipophilicity and CNS penetration; pharmacokinetic data remains limited in peer-reviewed literature.

Longevity and Immune Peptides

• Epithalon (Epitalon) — Half-life: data limited, but peptide half-life is estimated under 2 hours in plasma. Research on telomere-related activity suggests downstream epigenetic effects persist well beyond plasma clearance.
• Thymosin Alpha-1 (Ta1) — Half-life: approximately 2 hours. Studies indicate robust immune-modulating activity that outlasts circulating concentrations, consistent with cytokine-mediated amplification effects.
• LL-37 (Cathelicidin) — Half-life: under 1 hour in plasma. Research suggests rapid deployment in innate immune responses with localized tissue activity.

Factors That Influence Peptide Half-Life

Half-life values are not fixed constants. Several variables can meaningfully shift how long a peptide remains active in a research system. Understanding these factors is essential for designing reproducible protocols.

• Route of administration: Subcutaneous injection typically yields longer plasma presence than intravenous delivery. Intranasal routes, used for neuropeptides like Semax, bypass first-pass metabolism entirely.
• Molecular modifications: PEGylation, DAC technology, and amino acid substitutions (such as D-amino acids) can dramatically extend half-life by blocking protease recognition sites.
• Temperature and storage: Peptide degradation accelerates outside recommended storage conditions. Most lyophilized peptides should be stored at -20°C and reconstituted solutions kept at 4°C for short-term use.
• pH and carrier solvents: Peptide stability in solution is highly pH-dependent. Bacteriostatic water at physiological pH ranges helps preserve integrity post-reconstitution.

Using Half-Life Data in Research Protocol Design

Half-life data should directly inform the timing intervals used in any structured peptide research protocol. Short-acting peptides like Sermorelin and GHRP-6 may require multiple administrations per day to maintain consistent receptor engagement. Long-acting peptides like CJC-1295 with DAC or TB-500 may only require weekly administration in research models.

Stacking protocols — combining peptides with complementary half-lives — are common in advanced research frameworks. For example, pairing Ipamorelin (2-hour half-life) with CJC-1295 without DAC (30-minute half-life) may create a synchronized GH pulse window in preclinical models, according to studies referenced in endocrinology literature.

Storage Best Practices to Preserve Peptide Integrity

Even the most stable peptide becomes unreliable if stored incorrectly. Lyophilized (freeze-dried) peptides from Maxx Laboratories are tested via HPLC for purity and shipped with integrity in mind. Once reconstituted, track your usage windows carefully and avoid repeated freeze-thaw cycles, which degrade secondary peptide structure.

Research-grade peptides from Maxx Laboratories include certificates of analysis with every order, giving researchers confidence in purity and concentration accuracy. [INTERNAL LINK: /products]

Disclaimer: All peptide products offered by Maxx Laboratories (maxxlaboratories.com) are intended for in vitro and laboratory research purposes only. These products are not intended for human consumption, veterinary use, or therapeutic application. They are not intended to treat, prevent, or mitigate any medical condition. All research should be conducted by qualified professionals in compliance with applicable regulations. Always consult a licensed healthcare provider before making any health-related decisions.